An open-label, prospective, non-comparative clinical trial to evaluate the efficacy and safety of rosuvastatin in high risk Indian population with diabetes and dyslipidemia

Trial Profile

An open-label, prospective, non-comparative clinical trial to evaluate the efficacy and safety of rosuvastatin in high risk Indian population with diabetes and dyslipidemia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Dyslipidaemias
  • Focus Therapeutic Use
  • Acronyms RESIDD
  • Sponsors Ranbaxy Laboratories
  • Most Recent Events

    • 08 May 2009 New source identified and integrated (Australian New Zealand Clinical Trials RegistryACTRN12607000473460).
    • 27 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top